Editas Medicine Inc - Asset Resilience Ratio
Editas Medicine Inc (EDIT) has an Asset Resilience Ratio of 12.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EDIT current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Editas Medicine Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Editas Medicine Inc.
Liquid Assets Composition Over Time
This chart breaks down Editas Medicine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore EDIT long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $29.83 Million | 12.57% |
| Total Liquid Assets | $29.83 Million | 12.57% |
Asset Resilience Insights
- Moderate Liquidity: Editas Medicine Inc has 12.57% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Editas Medicine Inc Industry Peers by Asset Resilience Ratio
Compare Editas Medicine Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN |
Biotechnology | 83.46% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Editas Medicine Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Editas Medicine Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $186.53 Million | -- |
| 2024-12-31 | 40.51% | $138.37 Million | $341.59 Million | +0.55pp |
| 2023-12-31 | 39.96% | $199.46 Million | $499.15 Million | +0.54pp |
| 2022-12-31 | 39.42% | $202.75 Million | $514.32 Million | -4.32pp |
| 2021-12-31 | 43.74% | $296.33 Million | $677.48 Million | -2.09pp |
| 2020-12-31 | 45.83% | $262.43 Million | $572.60 Million | +2.80pp |
| 2019-12-31 | 43.03% | $218.96 Million | $508.88 Million | -12.68pp |
| 2018-12-31 | 55.71% | $234.18 Million | $420.39 Million | +6.81pp |
| 2017-12-31 | 48.90% | $182.51 Million | $373.26 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $229.18 Million | -- |
| 2015-12-31 | 0.21% | $320.00K | $149.36 Million | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more